Dipropyltryptamine
| Clinical data | |
|---|---|
| Other names | DPT; N,N-Dipropyltryptamine | 
| Routes of administration | Oral, inhalation (smoking), intravenous or intramuscular injection | 
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen | 
| ATC code | 
 | 
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Injection: 10–15 minutes | 
| Duration of action | 2–4 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H24N2 | 
| Molar mass | 244.382 g·mol−1 | 
| 3D model (JSmol) | |
| Melting point | 174.5 to 178 °C (346.1 to 352.4 °F) | 
| 
 | |
| 
 | |
| (verify) | |
N,N-Dipropyltryptamine (DPT) is a psychedelic drug and entheogen belonging to the tryptamine family. Use as a designer drug has been documented by law enforcement officials since as early as 1968. However, potential therapeutic use was not investigated until the 1970s. It is found either as a crystalline hydrochloride salt or as an oily or crystalline base. It has not been found to occur endogenously. It is a close structural homologue of dimethyltryptamine and diethyltryptamine.